PL362173A1 - Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use - Google Patents

Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use

Info

Publication number
PL362173A1
PL362173A1 PL01362173A PL36217301A PL362173A1 PL 362173 A1 PL362173 A1 PL 362173A1 PL 01362173 A PL01362173 A PL 01362173A PL 36217301 A PL36217301 A PL 36217301A PL 362173 A1 PL362173 A1 PL 362173A1
Authority
PL
Poland
Prior art keywords
compounds
production
medicaments containing
azetidinone derivatives
diphenyl azetidinone
Prior art date
Application number
PL01362173A
Other languages
English (en)
Polish (pl)
Inventor
Heiner Glombik
Werner Kramer
Stefanie Flohr
Wendelin Frick
Hubert Heuer
Gerhard Jaehne
Andreas Lindenschmidt
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10064402A external-priority patent/DE10064402A1/de
Priority claimed from DE2001154520 external-priority patent/DE10154520A1/de
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of PL362173A1 publication Critical patent/PL362173A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL01362173A 2000-12-21 2001-12-11 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use PL362173A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10064402A DE10064402A1 (de) 2000-12-21 2000-12-21 Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE2001154520 DE10154520A1 (de) 2001-11-07 2001-11-07 Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP2001/014532 WO2002050068A1 (de) 2000-12-21 2001-12-11 Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (1)

Publication Number Publication Date
PL362173A1 true PL362173A1 (en) 2004-10-18

Family

ID=26008045

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01362173A PL362173A1 (en) 2000-12-21 2001-12-11 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use

Country Status (23)

Country Link
US (1) US6498156B2 (cg-RX-API-DMAC7.html)
EP (1) EP1345932B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004516293A (cg-RX-API-DMAC7.html)
KR (1) KR20030061462A (cg-RX-API-DMAC7.html)
CN (1) CN1222522C (cg-RX-API-DMAC7.html)
AR (1) AR034282A1 (cg-RX-API-DMAC7.html)
AT (1) ATE342899T1 (cg-RX-API-DMAC7.html)
AU (2) AU1917302A (cg-RX-API-DMAC7.html)
BR (1) BR0116482A (cg-RX-API-DMAC7.html)
CA (1) CA2431985A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031731A3 (cg-RX-API-DMAC7.html)
DE (1) DE50111293D1 (cg-RX-API-DMAC7.html)
EE (1) EE200300237A (cg-RX-API-DMAC7.html)
HR (1) HRP20030499A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0401067A2 (cg-RX-API-DMAC7.html)
IL (1) IL156552A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03005018A (cg-RX-API-DMAC7.html)
NO (1) NO20032733L (cg-RX-API-DMAC7.html)
NZ (1) NZ526592A (cg-RX-API-DMAC7.html)
PL (1) PL362173A1 (cg-RX-API-DMAC7.html)
SK (1) SK7812003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002050068A1 (cg-RX-API-DMAC7.html)
YU (1) YU46903A (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
MXPA03005155A (es) * 2000-12-21 2003-09-10 Aventis Pharma Gmbh 1,2-difenilazetidinonas novedosas, procesos para su preparacion, farmacos que contienen compuestos y su uso para el tratamiento del metabolismo afectado de los lipidos.
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
NZ545332A (en) * 2001-01-26 2007-09-28 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
MEP27808A (en) * 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
HRP20040171A2 (en) * 2001-08-22 2004-10-31 Aventis Pharma Gmbh Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227507A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AU2003254261B2 (en) * 2002-07-30 2008-04-17 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
CA2525367A1 (en) * 2003-05-09 2004-11-25 The Trustees Of The University Of Pennsylvania Use of citrate lyase inhibitors and tricarboxylate transporter inhibitors in the treatment of cancer
EP1660456A2 (en) * 2003-08-25 2006-05-31 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
AP2006003832A0 (en) * 2004-01-20 2006-12-31 Panacea Biotec Ltd Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
KR20060129082A (ko) 2004-03-05 2006-12-14 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과연관된 질환 또는 질병의 치료 방법
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
AU2005299771A1 (en) * 2004-10-21 2006-05-04 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
EP1819684B1 (en) 2004-12-03 2013-08-07 Intervet International B.V. Substituted piperazines as cb1 antagonists
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
BRPI0611531A2 (pt) * 2005-05-09 2010-09-21 Microbia Inc agentes de acoplamento de benzenofosfonato de organometal e método de geração de ligação carbono-carbono
CN101218213A (zh) * 2005-05-11 2008-07-09 迈克罗比亚公司 制备酚类4-联苯基氮杂环丁烷-2-酮的方法
US20090099355A1 (en) * 2005-05-25 2009-04-16 Microbia, Inc. Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
AU2006262441A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine H3 antagonists
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
CA2626461A1 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
WO2007084450A2 (en) * 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
EP2059241A1 (en) * 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008039829A2 (en) * 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
DE102007002260A1 (de) * 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
AU2008271178A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as CB1 antagonists
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
AU2010288523A1 (en) 2009-08-26 2012-03-15 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102746249B (zh) * 2012-07-07 2013-12-25 山东诚创医药技术开发有限公司 一种依折麦布中间体的纯化精制方法
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
PT781278E (pt) * 1994-09-13 2001-08-30 Monsanto Co Novas benzotiepinas com actividade inibidora do transporte de acido biliar ileal e da remocao do taurocolato
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
NO20032733D0 (no) 2003-06-16
DE50111293D1 (de) 2006-11-30
KR20030061462A (ko) 2003-07-18
US6498156B2 (en) 2002-12-24
BR0116482A (pt) 2004-02-03
AR034282A1 (es) 2004-02-18
CN1481381A (zh) 2004-03-10
MXPA03005018A (es) 2003-09-25
SK7812003A3 (en) 2004-01-08
NO20032733L (no) 2003-08-14
EP1345932A1 (de) 2003-09-24
NZ526592A (en) 2004-11-26
CZ20031731A3 (cs) 2003-09-17
AU2002219173B2 (en) 2006-06-22
JP2004516293A (ja) 2004-06-03
WO2002050068A1 (de) 2002-06-27
IL156552A0 (en) 2004-01-04
EP1345932B1 (de) 2006-10-18
ATE342899T1 (de) 2006-11-15
AU1917302A (en) 2002-07-01
US20020128252A1 (en) 2002-09-12
YU46903A (sh) 2006-05-25
HUP0401067A2 (hu) 2004-09-28
HK1059936A1 (en) 2004-07-23
CA2431985A1 (en) 2002-06-27
EE200300237A (et) 2003-08-15
HRP20030499A2 (en) 2005-04-30
CN1222522C (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
IL156552A0 (en) Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
IL156548A0 (en) Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
AU2002219173A1 (en) Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
HUS1400005I1 (hu) Kinazolinszármazékok, elõállításuk, alkalmazásuk és ezeket tartalmazó gyógyszerek
ZA200102588B (en) Aryl-substituted propanolamine derivatives, methods for their production, medicaments containing said compounds and their use.
HUP0300819A3 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
AU2001295481A1 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
AU2001287694A1 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
MXPA03000873A (es) Derivados de quinazolina, medicamentos que contienen estos compuestos, su uso y metodos para la produccion de los mismos.
HUP0401081A3 (en) Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
IL147133A0 (en) Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
AU2002219174A1 (en) Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
PL345863A1 (en) Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments
IL150377A0 (en) Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
MXPA03001510A (es) Heterociclos biciclicos, medicamentos que contiene estos compuestos, su empleo y procedimientos para su preparacion.
HRP20041203A2 (en) Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
AU2003226806A1 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and method for the production thereof
PL376399A1 (en) Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
HUP0204360A3 (en) Substituted norbornylamino derivatives, method for the production thereof, use thereof as a medicament and medicaments containing said compounds
HUP0001249A3 (en) Novel substituted dimeric compounds, process for their production and medicaments containing the same
ZA200110351B (en) Bycyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof.
MXPA03008636A (es) Derivados de isoquinuclidina, metodo para fabricar los mismos y agentes terapeuticos que contienen estos compuestos.
HU0001178D0 (en) New propene-carbon acid-amidoxim derivatives, process for their production and medicaments containing the same
SI1560826T1 (sl) Spojine piridopirimidinona, postopek za njihovo pripravo in farmacevtski sestavki, ki te vsebujejo

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)